Patients with resectable or borderline resectable pancreatic cancer who receive neoadjuvant chemoradiotherapy have better outcomes than their counterparts who proceed directly to surgery, suggest phase III trial results.

Adjuvant treatment with a modified FOLFIRINOX regimen significantly improves survival relative to gemcitabine in patients with resected pancreatic ductal adenocarcinoma, according to findings presented at the ASCO Annual Meeting 2018, held in Chicago, Illinois, USA.

Preliminary findings from the PREOPANC -1 trial suggest that neoadjuvant chemoradiotherapy may be beneficial for patients with resectable pancreatic cancer. Lead author Geertjan Van Tienhoven outlines the results and discusses the challenges of conducting this trial. (3:46) Watch the accompanying expert commentary .

Presenting author Thierry Conroy provides an overview of the PRODIGE 24 trial showing adjuvant modified FOLFIRINOX outplays gemcitabine in patients with operable pancreatic cancer (3:58). Read the related news story Watch the accompanying expert commentary

Postmenopausal women who take short-acting calcium channel blockers could be at increased risk for developing pancreatic cancer, findings indicate.

Patients with borderline resectable or locally advanced pancreatic cancer experience a significant loss of adipose tissue along with an increase in muscle mass during neoadjuvant therapy that may improve the odds for resection, researchers report.

Deleterious germline mutations are common in patients with pancreatic ductal adenocarcinoma who do not have a family history of the disease, research suggests.

Researchers report promising results from a phase I trial evaluating CPI-613, which targets mitochondrial metabolism, in combination with modified FOLFIRINOX chemotherapy for the treatment of metastatic pancreatic cancer.

A nanoparticle-based assay that detects tumor-derived extracellular vesicles in plasma samples could not only improve pancreatic cancer diagnosis, but also aid treatment monitoring, say researchers who conducted a proof-of-concept study.

Findings presented at the 36th European Society for Radiation and Oncology conference suggest that patients with early-stage pancreatic cancer could derive an overall survival benefit from high doses of adjuvant radiotherapy given alongside chemotherapy.

They were aged a median of 65 years and 60 had non-small-cell lung cancer (NSCLC), while 55 had colorectal cancer (CRC) and 22 had other solid tumors.

Patients with a new diagnosis or rapid deterioration of type 2 diabetes should be considered for pancreatic cancer, suggested research presented at the European Cancer Congress in Amsterdam.

Germline mutations in six cancer predisposition genes are associated with pancreatic cancer, with approximately one in 20 patients harboring a mutation in at least one of these genes, shows a case–control study.